Potential Impact of New Strategies of Infant Immunization in the Disease and Economic burden of RSV in Colombia
Author(s)
MARIA CARRASQUILLA SOTOMAYOR, BEc, MSc1, Nelson José Alvis Zakzuk, MSc2, Wilfrido Coronell, MEd, Phd3, Nelson R. Alvis Zakzuk, MBA4, Juan C. Alvarado-Gonzalez, MEd, MSc4, Andrés Arias, MEd, MSc5, Lina M. Moyano, BEc4, Fernando De La Hoz, MEd, PhD6, Nelson Alvis-Guzman, MPH, PhD, MD3;
1ALZAK, Researcher, São Paulo, Brazil, 2Universidad de la Costa, Barranquilla, Colombia, 3Universidad de Cartagena, Cartagena, Colombia, 4ALZAK, Cartagena, Colombia, 5Infectoped, Cúcuta, Colombia, 6Universidad Nacional de Colombia, Bogotá, Colombia
1ALZAK, Researcher, São Paulo, Brazil, 2Universidad de la Costa, Barranquilla, Colombia, 3Universidad de Cartagena, Cartagena, Colombia, 4ALZAK, Cartagena, Colombia, 5Infectoped, Cúcuta, Colombia, 6Universidad Nacional de Colombia, Bogotá, Colombia
OBJECTIVES: In Colombia, Respiratory Syncytial Virus (RSV) is endemic and associated with high morbidity and mortality rates, especially in infants <2 years old. RSV prophylaxis technologies have shown to be effective immunization strategies to reduce disease burden. This study evaluates the health and economic impact of new RSV immunization technologies in Colombia.
METHODS: A static cohort decision model from a third-party payer perspective was developed to assess the public health impact of three immunization strategies: 1) nirsevimab year-round vaccination (YRV) for newborn entering the RSV-season, 2) nirsevimab with seasonal vaccination with catch up (SVCU) for all <1 year old infants, and 3) year-round vaccination with RSV-PreF for pregnant women (32-36+6 weeks of gestation). These were compared to the standard of care (SoC - palivizumab in high-risk infants). Outcomes included RSV cases, hospitalizations (including ICU and mechanical ventilation), primary care visits, emergency room visits, deaths, costs, and QALYs. Efficacies were derived from clinical studies and indirect comparisons were performed since there were no head-to-head trials, while costs and health events were estimated using local data and literature.
RESULTS: Under the SoC, 249,483 RSV cases were estimated. Nirsevimab SVCU prevented the highest number of RSV cases and hospitalizations (86,589 and 8,571, respectively), followed by nirsevimab YRV (44,031 and 6,209) and RSV-PreF (29,481 and 3,953) in comparison with SoC. The number needed to immunize to prevent one RSV case was 6 for N-SVCU, 11 for N-YRV, and 13 for RSV-PreF. Compared to RSV-PreF, nirsevimab strategies gained from 219 to 604 additional QALYs and would save between US$8,438,626-$18,587,263 from avoided RSV-related direct costs.
CONCLUSIONS: Nirsevimab and RSV-PreF versus SoC effectively prevented RSV cases and improved health outcomes in Colombian infants. Nirsevimab demonstrated the greatest impact in reducing disease burden. Incorporating nirsevimab into national immunization program could significantly reduce the economic and disease burden of RSV.
METHODS: A static cohort decision model from a third-party payer perspective was developed to assess the public health impact of three immunization strategies: 1) nirsevimab year-round vaccination (YRV) for newborn entering the RSV-season, 2) nirsevimab with seasonal vaccination with catch up (SVCU) for all <1 year old infants, and 3) year-round vaccination with RSV-PreF for pregnant women (32-36+6 weeks of gestation). These were compared to the standard of care (SoC - palivizumab in high-risk infants). Outcomes included RSV cases, hospitalizations (including ICU and mechanical ventilation), primary care visits, emergency room visits, deaths, costs, and QALYs. Efficacies were derived from clinical studies and indirect comparisons were performed since there were no head-to-head trials, while costs and health events were estimated using local data and literature.
RESULTS: Under the SoC, 249,483 RSV cases were estimated. Nirsevimab SVCU prevented the highest number of RSV cases and hospitalizations (86,589 and 8,571, respectively), followed by nirsevimab YRV (44,031 and 6,209) and RSV-PreF (29,481 and 3,953) in comparison with SoC. The number needed to immunize to prevent one RSV case was 6 for N-SVCU, 11 for N-YRV, and 13 for RSV-PreF. Compared to RSV-PreF, nirsevimab strategies gained from 219 to 604 additional QALYs and would save between US$8,438,626-$18,587,263 from avoided RSV-related direct costs.
CONCLUSIONS: Nirsevimab and RSV-PreF versus SoC effectively prevented RSV cases and improved health outcomes in Colombian infants. Nirsevimab demonstrated the greatest impact in reducing disease burden. Incorporating nirsevimab into national immunization program could significantly reduce the economic and disease burden of RSV.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE290
Topic
Economic Evaluation
Disease
SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), STA: Vaccines